Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $107.25 Consensus PT from Brokerages

Shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) have earned a consensus recommendation of “Moderate Buy” from the fourteen ratings firms that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $110.1667.

A number of equities research analysts have weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Friday, December 19th. Raymond James Financial reiterated a “strong-buy” rating and set a $110.00 price objective on shares of Mirum Pharmaceuticals in a research report on Thursday, December 11th. TD Cowen reissued a “buy” rating on shares of Mirum Pharmaceuticals in a research report on Monday, January 12th. Evercore restated an “outperform” rating and set a $101.00 price target on shares of Mirum Pharmaceuticals in a research note on Tuesday, January 20th. Finally, HC Wainwright increased their price objective on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the stock a “buy” rating in a research note on Monday, January 26th.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, CFO Eric Bjerkholt sold 1,421 shares of the company’s stock in a transaction dated Thursday, January 22nd. The stock was sold at an average price of $93.33, for a total value of $132,621.93. Following the completion of the sale, the chief financial officer owned 42,127 shares in the company, valued at $3,931,712.91. This represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Christopher Peetz sold 9,108 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $103.30, for a total value of $940,856.40. Following the completion of the transaction, the chief executive officer directly owned 160,294 shares in the company, valued at $16,558,370.20. This trade represents a 5.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 45,136 shares of company stock valued at $4,352,029. 22.87% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. Freestone Grove Partners LP bought a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth approximately $450,000. Guggenheim Capital LLC purchased a new position in shares of Mirum Pharmaceuticals during the 4th quarter valued at $772,000. Logos Global Management LP bought a new position in Mirum Pharmaceuticals in the 4th quarter worth $17,773,000. AQR Capital Management LLC increased its stake in Mirum Pharmaceuticals by 3.5% in the 4th quarter. AQR Capital Management LLC now owns 32,485 shares of the company’s stock worth $2,566,000 after buying an additional 1,090 shares in the last quarter. Finally, Cetera Investment Advisers increased its stake in Mirum Pharmaceuticals by 39.0% in the 4th quarter. Cetera Investment Advisers now owns 6,170 shares of the company’s stock worth $487,000 after buying an additional 1,732 shares in the last quarter.

Mirum Pharmaceuticals Stock Performance

Shares of MIRM stock opened at $102.83 on Friday. The company has a quick ratio of 3.16, a current ratio of 3.31 and a debt-to-equity ratio of 1.06. The company has a 50 day moving average price of $87.83 and a 200-day moving average price of $76.82. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $105.74. The firm has a market capitalization of $5.28 billion, a PE ratio of -119.57 and a beta of 0.49.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.